The 1989 Noble prize winner in Chemistry, Prof. Thomas R. Cech, from the University of Colorado BioFrontiers Institute, USA, has published a research paper in the 13 December 2012 Nature (492(7428):285-9; and I.F: >42) stating that “The TEL patch of telomere protein TPP1 mediates telomerase recruitment and processivity.” This study provides mechanistic insights into how TPP1 regulates telomerase function.
In connection with this finding, Dr Boominathan, Founder Director-cum-chief scientist of GBMD, reports that: Molecular therapy for Human Cancer: Enhancer of zeste homolog 2 suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) via up regulation of its target gene. Remarkably, over 90% human tumors over express telomerase, suggesting that inhibition of its activity may increase the efficacy of anticancer therapy. Together, this study suggests that pharmacological formulations containing “Enhancer of zeste homolog 2 activators” can be used in the treatment of human cancers.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Molecular therapy for Human Cancer: Enhancer of zeste homolog 2 suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) via up regulation of its target gene, 20/April/2015, 6.58 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
Undisclosed information: How Enhancer of zeste homolog 2 suppresses the expression of TPP1
